Tests modified immune T cells targeting CD7 in certain blood cancers
Tests engineered immune T cells aimed at CD7 in blood cancers.
Plain-language title generated from the registry record
Registry title: Universal 4SCAR7U Targeting CD7-positive Malignancies
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with CD7-positive blood cancers, such as T-cell leukemia or lymphoma, acute myeloid leukemia or NK cell lymphoma. It tests CAR T cells that target CD7.
- Age
- From 6 Months to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Cancer cells must show CD7 and other surface markers on a lab test. Life expectancy must be more than 3 months.
- Earlier treatment
- People who had any gene therapy product before cannot join. No systemic glucocorticoid within one week before the trial.
- Biomarker or test result
- CD7 must be confirmed on the cancer cells by immuno-histochemical staining or flow cytometry.
Main reasons for not taking part
- Known HIV or hepatitis C virus (HCV) infection
- Pregnant or nursing women
- Active infection that is not controlled by treatment
- Previous treatment with any gene therapy product
- Systemic glucocorticoid use within one week before the trial
Read by machine on 9 November 2026.
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT05995028
- Record updated
- 2 November 2026
- Original description
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.Read full original descriptionShow less
Safety and Efficacy of Universal 4SCAR7U T Cell Therapy Targeting CD7-positive Hematological Malignancies
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.
Inclusion: Age older than 6 months; Confirmed expression of CD7 and additional surface antigens in the cancer cells by immuno-histochemical staining or flow cytometry; Karnofsky performance status (KPS) score is higher than 80 and life expectancy > 3 months; Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%, creatinine ≤ 2.5 × upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal, total bilirubin ≤ 2.0mg/dL; Hgb≥80g/L; No cell separation contraindications; Abilities to understand and the willingness to provide written informed consent.
Exclusion: Use of glucocorticoid for systemic therapy within one week prior to entering the trial; Previous treatment with any gene therapy products; Sever illness or medical condition, which would not permit the patient to be managed according to the protocol, including active uncontrolled infection; Active bacterial, fungal or viral infection not controlled by adequate treatment; Known HIV or hepatitis C virus (HCV) infection; Pregnant or nursing women may not participate; Patients, in the opinion of investigators, may not be able to comply with the study.